Table 3.

Follow-up of clinical outcomes and medication use until 5 years for study population split for change in left ventricular ejection fraction between 4 months and 24 months

	LVEF improvement  (n=78%)	LVEF deterioration  (n=77%)	p Value
Medication at 4 months
ACE-inhibitors/ATII antagonists	72 (92)	69 (90)	0.32
Beta-blockers	72 (92)	69 (90)	0.56
Medication at 2 years
ACE-inhibitors/ATII antagonists	73 (94)	67 (87)	0.35
Beta-blockers	75 (96)	61 (80)	0.004
NYHA class I
4 months	63 (81)	66 (86)	0.41
2 years	64 (82)	70 (92)	0.06
Hospitalisation for heart failure
2 years	1 (1)	2 (3)	0.56
5 years	3 (4)	1 (1)	0.56
Repeat PCI
2 years	17 (21)	16 (21)	0.88
5 years	18 (23)	18 (23)	1.00
CABG
2 years	0 (0)	0 (0)	1.00
Recurrent myocardial infarction*
5 years	1 (1.3)	3 (4)	0.31
Mortality*
5 years	3 (4)	1 (1)	0.31

*Patients who died (n=3) or suffered recurrent myocardial infarction (n=4) in the first 24 months after PCI were not included in this substudy.

AT, angiotensin; CABG, coronary artery bypass grafting; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.